Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 171.30K | 265.00K | 177.50K | 161.10K | 226.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 171.30K | 265.00K | 177.50K | 161.10K | 226.70K |
| Cost of Revenue | 76.50K | 106.10K | 90.80K | 139.90K | 58.00K |
| Gross Profit | 94.80K | 158.90K | 86.70K | 21.20K | 168.80K |
| SG&A Expenses | 552.70K | 469.80K | 309.10K | 621.10K | 455.50K |
| Depreciation & Amortization | 111.90K | 105.20K | 108.00K | 210.70K | 83.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 814.70K | 682.50K | 520.30K | 1.02M | 621.10K |
| Operating Income | -643.40K | -417.50K | -342.80K | -860.40K | -394.40K |
| Income Before Tax | -718.60K | -548.20K | -417.80K | -966.30K | -432.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -718.60K | -548.20K | -417.80K | -966.30K | -432.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -718.60K | -548.20K | -417.80K | -966.30K | -432.80K |
| EBIT | -643.40K | -417.50K | -342.80K | -860.40K | -394.40K |
| EBITDA | -584.30K | -366.40K | -288.00K | -797.60K | -364.80K |
| EPS Basic | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 103.89M | 103.42M | 103.42M | 103.59M | 103.36M |
| Average Diluted Shares Outstanding | 103.89M | 103.42M | 103.42M | 103.59M | 103.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |